跳转至内容
Merck

N-905

Supelco

去甲地西泮标准液 溶液

1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H11ClN2O
CAS号:
分子量:
270.71
EC號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

形狀

liquid

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

濃度

1 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

儲存溫度

−20°C

SMILES 字串

Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1

InChI

1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)

InChI 密鑰

AKPLHCDWDRPJGD-UHFFFAOYSA-N

一般說明

去甲西泮是一种苯二氮卓类药物,用于治疗焦虑症和恐慌症。该分析标准物质适用于LC/MS或GC/MS应用,以进行临床毒理学研究、法医分析或尿液药物检测。去甲西泮也是苯二氮卓类药物地西泮和氯氮卓的主要尿液代谢产物。

推薦產品

在我们的NMR在线平台ChemisTwin®上可以找到本品对应的数字化标准物质。您可使用ChemisTwin®上的数字等效品鉴定您的样品并进行定量分析(使用数字化外标)。可查看该物质的NMR谱图,只需点击几次鼠标,就能进行在线样品比对。欢迎点击了解更多,开启免费试用之旅。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Craig Lehmann et al.
Journal of clinical pharmacology, 48(4), 436-444 (2008-02-02)
A diazepam 10-mg autoinjector was evaluated in bioequivalence and dose proportionality studies; both involved 24 young, healthy subjects and used randomized, open-label, 2-treatment, 2-period crossover designs with a 3-week washout period between treatments. The bioequivalence study compared a single diazepam
Shanlin Fu et al.
Journal of analytical toxicology, 34(5), 243-251 (2010-06-10)
beta-Glucuronidase is an enzyme often employed to de-conjugate beta-glucuronides during urinary drug testing for benzodiazepines. It is commonly accepted that use of beta-glucuronidase is a preferred method of hydrolysis over acid-catalyzed hydrolysis, which is known to induce benzodiazepine degradation and
David A Fishbain et al.
Pain medicine (Malden, Mass.), 10(3), 565-572 (2008-11-11)
The objectives of this medicolegal case report are the following: 1) to present details of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT), and subsequently overdosed on multiple drugs, some of which were not
Ali Acikgöz et al.
Toxicology and applied pharmacology, 234(2), 179-191 (2008-11-06)
Drug biotransformation is one of the most important parameters of preclinical screening tests for the registration of new drug candidates. Conventional existing tests rely on nonhuman models which deliver an incomplete metabolic profile of drugs due to the lack of
Joris C Verster et al.
Sleep medicine reviews, 17(2), 153-159 (2012-08-14)
The use of benzodiazepine receptor agonists can significantly impair driving performance. The aim of this review was to determine if there is a relation between blood concentrations of these drugs and the degree of driving impairment. A literature search was

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门